These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 26506117)
21. [Calprotectin levels in patients with idiopathic inflammatory bowel disease comparison of two commercial tests]. Malícková K; Janatková I; Bortlík M; Komárek V; Lukás M Epidemiol Mikrobiol Imunol; 2008 Nov; 57(4):147-53. PubMed ID: 19069028 [TBL] [Abstract][Full Text] [Related]
22. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Coorevits L; Baert FJ; Vanpoucke HJ Clin Chem Lab Med; 2013 Apr; 51(4):825-31. PubMed ID: 23001318 [TBL] [Abstract][Full Text] [Related]
23. A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease. Lee JM; Jang JH; Ryu JH; Yoo J; Lee BI; Kim SJ; Oh EJ PLoS One; 2021; 16(8):e0255974. PubMed ID: 34383847 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Dolwani S; Metzner M; Wassell JJ; Yong A; Hawthorne AB Aliment Pharmacol Ther; 2004 Sep; 20(6):615-21. PubMed ID: 15352909 [TBL] [Abstract][Full Text] [Related]
26. Faecal calprotectin: a new marker for Crohn's disease? Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438 [TBL] [Abstract][Full Text] [Related]
27. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Costa F; Mumolo MG; Ceccarelli L; Bellini M; Romano MR; Sterpi C; Ricchiuti A; Marchi S; Bottai M Gut; 2005 Mar; 54(3):364-8. PubMed ID: 15710984 [TBL] [Abstract][Full Text] [Related]
28. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498 [TBL] [Abstract][Full Text] [Related]
29. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab. Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391 [TBL] [Abstract][Full Text] [Related]
30. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461 [TBL] [Abstract][Full Text] [Related]
31. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12. Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301 [TBL] [Abstract][Full Text] [Related]
32. Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease. Eder P; Stawczyk-Eder K; Krela-Kaźmierczak I; Linke K Pol Arch Med Wewn; 2008 Nov; 118(11):622-6. PubMed ID: 19140565 [TBL] [Abstract][Full Text] [Related]
33. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083 [TBL] [Abstract][Full Text] [Related]
34. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Kristensen V; Malmstrøm GH; Skar V; Røseth A; Moum B Scand J Gastroenterol; 2016; 51(5):548-55. PubMed ID: 26634305 [TBL] [Abstract][Full Text] [Related]
35. Impact of disease location on fecal calprotectin levels in Crohn's disease. Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819 [TBL] [Abstract][Full Text] [Related]
36. Faecal calprotectin in the assessment of Crohn's disease activity. Gaya DR; Lyon TD; Duncan A; Neilly JB; Han S; Howell J; Liddell C; Stanley AJ; Morris AJ; Mackenzie JF QJM; 2005 Jun; 98(6):435-41. PubMed ID: 15879440 [TBL] [Abstract][Full Text] [Related]
37. Correlation Between Calprotectin and Modified Rutgeerts Score. Lopes S; Andrade P; Afonso J; Rodrigues-Pinto E; Dias CC; Macedo G; Magro F Inflamm Bowel Dis; 2016 Sep; 22(9):2173-81. PubMed ID: 27482974 [TBL] [Abstract][Full Text] [Related]
38. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study. Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068 [TBL] [Abstract][Full Text] [Related]
39. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964 [TBL] [Abstract][Full Text] [Related]
40. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]